EVALUATION OF THE BENEFICIAL EFFECTS OF ASPIRIN AND ATORVASTATIN SEPARATELY AND COMBINED ON HYPERURICEMIC RAT MODEL
Main Article Content
Keywords
Hyperuricemia, Aspirin, Atorvastatin
Abstract
Introduction: Low doses of aspirin and statins are commonly prescribed together for patients with coronary artery disease. Aspirin at low doses is known to cause hyperuricemia in these patients while there is some evidence that atorvastatin may have a hypouricemic action but underlying mechanism remain speculative. In this study we will investigate the effects of atorvastatin and aspirin alone and in combination on serum uric acid of hyperuricemic rats. Aims & Objectives: To estimate the effect of atorvastatin and low dose of aspirin alone and in combination on serum uric acid level and urinary uric acid excretion in hyperuricemic rats. Place and duration of study: Post Graduate Medical Institute, Lahore from November 2019 to April 2020. Material & Methods: Thirty rats were divided into five groups of six rats each. Group I and II were given distilled water, III, IV and V were given aspirin alone, atorvastatin alone and combination of aspirin and atorvastatin, respectively, as a single morning dose for 7 days. Group I was given normal saline and group II, III, IV and V was given potassium oxonate on day 1, 3 and 7. One ml blood and twenty-four-hour urine sample was collected on week 0 and 4 for estimation of uric acid and creatinine concentrations. Fractional excretion of uric acid was calculated Results: The serum uric acid levels rose significantly in disease control and all other experimental group between day 0 and 7. Between day 0 and 7, there was no significant change in urinary uric acid level of normal control group, while the values became significantly high in all other groups between day 0 and 7. There was significant rise in urine creatinine of aspirin and atorvastatin combined group between day 0 and 7. The percentage decrease as compared to day 0 was highest in atorvastatin group followed by combined aspirin and atorvastatin group and aspirin alone treated group.
Conclusion: The results could not affirm the hypothesis of nullifying the hyperuricemia effect of low dose aspirin with the addition of atorvastatin in the hyperuricemic rats.
References
2. Athyros, V.G., Mikhailidis, D.P., Liberopoulos, E.N., Kakafika, A.I., Karagiannis, A., Papageorgiou, A.A., Tziomalos, K., Ganotakis, E.S. and Elisaf, M., 2007. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrology Dialysis Transplantation, 22(1), pp.118-127.
3. Bellis, A., Di Gioia, G., Mauro, C., Mancusi, C., Barbato, E., Izzo, R., Trimarco, B. and Morisco, C., 2021. Reducing cardiac injury during ST-elevation myocardial infarction: a reasoned approach to a multitarget therapeutic strategy. Journal of Clinical Medicine, 10(13), p.2968.
4. Ben Salem, C., Slim, R., Fathallah, N. and Hmouda, H., 2017. Drug-induced hyperuricaemia and gout. Rheumatology, 56(5), pp.679-688.
5. Cai, T., Abel, L., Langford, O., Monaghan, G., Aronson, J.K., Stevens, R.J., Lay-Flurrie, S., Koshiaris, C., McManus, R.J., Hobbs, F.R. and Sheppard, J.P., 2021. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. Bmj, 374.
6. Du, L., Zong, Y., Li, H., Wang, Q., Xie, L., Yang, B., Pang, Y., Zhang, C., Zhong, Z. and Gao, J., 2024. Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy, 9(1), p.212.
7. Jones, W.S., Mulder, H., Wruck, L.M., Pencina, M.J., Kripalani, S., Muñoz, D., Crenshaw, D.L., Effron, M.B., Re, R.N., Gupta, K. and Anderson, R.D., 2021. Comparative effectiveness of aspirin dosing in cardiovascular disease. New England Journal of Medicine, 384(21), pp.1981-1990.
8. Kaufmann, D., Chaiyakunapruk, N. and Schlesinger, N., 2024. Optimizing Gout Treatment: A Comprehensive Review of Current and Emerging Uricosurics. Joint Bone Spine, p.105826.
9. Kose, E., An, T., Kikkawa, A., Matsumoto, Y. and Hayashi, H., 2014. Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients. Biological and Pharmaceutical Bulletin, 37(2), pp.226-231.
10. Li, J.R., Fan, Y. and Liu, M.L., 2021. Association between low-dose aspirin and uric acid in the elderly: an observational retrospective cross-sectional study. International journal of general medicine, pp.3635-3643.
11. Louthrenoo, W., Kasitanon, N., Wichainun, R. and Sukitawut, W., 2002. Effect of minidose aspirin on renal function and renal uric acid handling in healthy young adults. JCR: Journal of Clinical Rheumatology, 8(6), pp.299-304.
12. Milionis, H.J., Kakafika, A.I., Tsouli, S.G., Athyros, V.G., Bairaktari, E.T., Seferiadis, K.I. and Elisaf, M.S., 2004. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. American heart journal, 148(4), pp.635-640.
13. Pawar, M.K., 2017. Gouty tophi with purpura in a patient with ischemic heart disease and acute kidney injury. European Journal of Rheumatology, 5(2), p.149.
14. Ragab, G., Elshahaly, M. and Bardin, T., 2017. Gout: An old disease in new perspective–A review. Journal of advanced research, 8(5), pp.495-511.
15. Shahin, L., Patel, K.M., Heydari, M.K. and Kesselman, M.M., 2021. Hyperuricemia and cardiovascular risk. Cureus, 13(5).
16. Yan L,Ye L, Wang K, Zhou J, Zhu C. Atorvastatin improves reflow after percutaneous coronary intervention in patients with acute ST- segment elevation myocardial infarction by decreasing serum uric acid level. J. Zhejiang Univ. Med Sci. 2016; 45(5):530-535.
17. Zhang, P., Wang, H., Chen, X.H., Liang, W.Y., Liu, W.W. and Liu, M.L., 2020. Effect of low-dose aspirin on serum uric acid levels in Chinese individuals over 60: subanalysis of a multicentre randomized clinical trial. European Review for Medical & Pharmacological Sciences, 24(5).
18. Zuo, T., Liu, X., Jiang, L., Mao, S., Yin, X. and Guo, L., 2016. Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies. BMC cardiovascular disorders, 16, pp.1-10.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Usman Aslam
Assistant Professor, Department of Pharmacology, CMH Lahore Medical College, Lahore, Pakistan
Dr. Ayela Eman Zia
Assistant Professor, Department of Pharmacology, CMH Lahore Medical College, Lahore, Pakistan
Dr. Arooj Fatimah
Senior Demonstrator, Department of Pharmacology, CMH Lahore Medical College, Lahore and Pakistan
Dr. Waqar Ahmed Siddiqui
Associate Professor, Department of Pharmacology, CMH Lahore Medical College, Lahore, Pakistan
Dr. Sidra Zahid
Senior Demonstrator, Department of Pharmacology, CMH Lahore Medical College, Lahore and Pakistan
Dr. Gulpash Saghir
Associate Professor of Pharmacology, Fatima Jinnah Medical University, Lahore, Pakistan